{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.5","upperLimit":"91.6","value":"83.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants in the analysis population who achieved a complete response, partial response, or stable disease, as assessed by RECIST 1.1.","dispersionType":"90% Confidence Interval","groups":[{"description":"Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle plus Letrozole 2.5 mg administered orally daily for 28 days.","id":"OG000","title":"Ribociclib and Letrozole"}],"paramType":"NUMBER","populationDescription":"Eligible participants who received any amount of protocol therapy.","reportingStatus":"POSTED","timeFrame":"Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months.","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}